...
首页> 外文期刊>Journal of clinical laboratory analysis. >Application of high-throughput sequencing for hereditary thrombocytopenia in southwestern China
【24h】

Application of high-throughput sequencing for hereditary thrombocytopenia in southwestern China

机译:高通量测序在中国西南部遗传性血小板减少症的应用

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background The aim of this study was to design and analyze the applicability of a 21-gene high-throughput sequencing (HTS) panel in the molecular diagnosis of patients with hereditary thrombocytopenia (HT). Methods A custom target enrichment library was designed to capture 21 genes known to be associated with HTs. Twenty-four patients with an HT phenotype were studied using this technology. Results One pathogenic variant on the MYH9 gene and one likely pathogenic variant on the ABCG8 gene previously known to cause HTs were identified. Additionally, 3 previously reported variants affecting WAS , ADAMTS13 , and GP1BA were detected, and 9 novel variants affecting FLNA , ITGB3 , NBEAL2 , MYH9 , VWF , and ANKRD26 genes were identified. The 12 variants were classified to be of uncertain significance. Conclusion Our results demonstrate that HTS is an accurate and reliable method of pre-screening patients for variants in known HT-causing genes. With the advantage of distinguishing HT from immune thrombocytopenia, HTS could play a key role in improving the clinical management of patients.
机译:背景技术本研究的目的是设计和分析21-基因高通量测序(HTS)面板在遗传性血小板减少症(HT)患者的分子诊断中的适用性。方法旨在捕获已知与HTS相关联的21个基因的定制靶富集库。使用该技术研究了二十四名HT表型。结果鉴定了MyH9基因上的一种致病变体和先前已知原因HTS的ABCG8基因上的一个可能的致病变体。另外,检测到3例先前报告的变体,AdamTS13和GP1BA检测到,鉴定了9种影响FLNA,ITGB3,NBEAL2,MYH9,VWF和ANKRD26基因的9种新型变体。将12种变种分类为不确定的意义。结论我们的结果表明,HTS是预筛选HT引起基因中的患者的准确可靠的方法。随着区分HT从免疫血小板减少症的优势,HTS可以在改善患者的临床管理方面发挥关键作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号